Patents by Inventor Caroline Emery

Caroline Emery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEK mutations conferring resistance to MEK inhibitors
    Patent number: 9084781
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: July 21, 2015
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Carlos Garcia-Echeverria
  • C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS
    Publication number: 20150133478
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • BIOMARKERS FOR IAP INHIBITOR THERAPY
    Publication number: 20150105434
    Abstract: A method of selecting a subject having cancer for treatment with an IAP inhibitor.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 16, 2015
    Inventors: Dale Porter, John Scott Cameron, Caroline Emery, Douglas Robinson, Kavitha Venkatesan, Li Wang
  • BRAF Mutations Conferring Resistance to BRAF Inhibitors
    Publication number: 20140155399
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
    Type: Application
    Filed: December 4, 2013
    Publication date: June 5, 2014
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi Garraway, Caroline Emery
  • BRAF mutations conferring resistance to BRAF inhibitors
    Patent number: 8637246
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: January 28, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi Garraway, Caroline Emery
  • MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
    Publication number: 20130143911
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Application
    Filed: June 9, 2011
    Publication date: June 6, 2013
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS
    Publication number: 20120015973
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.
    Type: Application
    Filed: December 10, 2009
    Publication date: January 19, 2012
    Applicants: Novartis AG, Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Carlos Garcia Echeverria